Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Yoona Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Drug Approval, Clinical Trials as Topic, Research Personnel. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pivotal clinical trials (PCTs) are often conducted across multiple nations and regions to achieve geographic, racial, or ethnic diversity. However, the diversity of PCT participants remains inadequate. PCTs for new drugs approved by the US Food and Drug Administration in 2012–2021 and their primary publications (PPub) were identified from the label and review documents. The country information about the PCT investigators and PPub authors were extracted from the PPubs or clinicaltrials.gov . The racial/ethnic diversity of PCT participants as reported in PPubs was assessed using the Diversity Index (DI). For 429 new drugs, 734 PCTs and 718 PPubs were identified. North America and Western Europe (NAWE) contributed the largest proportion of PCT investigators, PPub authors, and lead authors (62.9%, 81.7%, and 90.9%, respectively). Of 521 PPubs that reported the racial/ethnic distribution of PCT participants, the median DI was low at 0.33 (interquartile range 0.18–0.46) and only 16.3% PPubs had a DI >0.5. The number of PPub authors in non‐NAWE and the number of countries of PPub authors in non‐NAWE was significantly associated with the racial/ethnic diversity of PCT participants (OR 1.17 [95% CI 1.08–1.26] and OR 1.25 [1.08–1.46], respectively). Evidence generation for the regulatory approval of new drugs has been predominantly centered in NAWE. The dominance is even more pronounced in the authorship of PPubs. To improve the racial/ethnic diversity of PCT participants, investigators from non‐NAWE countries should be encouraged to play more leadership roles, thereby increasing their likelihood of serving as authors in PPub.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
- Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
- Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, Republic of Korea.
- Advanced Institutes of Convergence Technology, Suwon, Republic of Korea.
ORCID-Profile: Yoona Choi, Jung-Hyun Won, Heeju Kim, YeSol Hong, Yujin Kim, Howard Lee
Zitieren
APA
Choi, Y., Won, J. H., Kim, H., Hong, Y., Kim, Y., & Lee, H. (2025). Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3589
Vancouver
Choi Y, Won JH, Kim H, Hong Y, Kim Y, Lee H. Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3589
BibTeX
@article{Choi2025,
author = {Choi, Yoona and Won, Jung-Hyun and Kim, Heeju and Hong, YeSol and Kim, Yujin and Lee, Howard},
title = {Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3589}
}
EUVIMED